The global Aptamers Market is estimated to be valued at US$ 6265.49 Mn in 2023 and is expected to exhibit a CAGR of 18.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Aptamers are short, single-stranded DNA or RNA molecules that bind to a specific target molecule like a protein, peptide, or other ligands. They can recognize molecules with high specificity and affinity similar to antibodies. Aptamers are cost-effective and stable, eliminating the need for animals during production. They have applications in molecular diagnostics, therapeutics development, proteomics, and clinical research. Compared to antibodies, aptamers feature better stability, low toxicity, small size, and high tissue penetration. Their synthetic nature allows modifications for enhanced specificity and affinity. These advantages widen their scope across various disease treatment and detection applications.

Market key trends:

The aptamers market is witnessing high growth due to increasing R&D in therapeutic areas like oncology, cardiovascular diseases, and infectious diseases. Growing focus on chronic diseases management is also propelling the market. Advancements in SELEX technology allow development of enhanced aptamers at lower costs. Increasing collaborations between market players and academic institutes are furthering clinical research on aptamers. Additional trends include development of cell-based and in vivo SELEX methods for creating cell-type and disease-specific diagnostic and therapeutic aptamers. Adoption of aptamers as an alternative to antibodies in clinical research also presents new opportunities.

Porter’s Analysis

Threat of new entrants: The aptamers market is dominated by major players which makes it difficult for new players to enter the market. The requirement of high R&D investments and stringent regulatory approvals further increases the entry barriers.

Bargaining power of buyers: The bargaining power of buyers is moderate as the industry is dominated by few major players. However, the availability of alternative therapeutic options provides some bargaining power to buyers.

Bargaining power of suppliers: The bargaining power of suppliers is low due to the availability of substitute raw materials. However, the switching cost from one supplier to another is high which increases suppliers’ bargaining power.

Threat of new substitutes: The threat of substitutes is moderate as there are alternative technologies available for target identification and validation. However, aptamers have advantages over other modalities limiting the threat.

Competitive rivalry: The competitive rivalry in the market is high due to the presence of major players fighting for a larger market share.

Key Takeaways

The Global Aptamers Market Size is expected to witness high growth, exhibiting CAGR of 18.4% over the forecast period, due to increasing R&D investments in drug discovery and increasing application of aptamers in therapeutics.

Regional analysis

North America dominates the global aptamers market owing to presence of major market players, high healthcare expenditure, and advanced scientific research infrastructure in the region. The Asia Pacific region is anticipated to exhibit the fastest growth during the forecast period due to increasing focus of key players to tap emerging Asian markets and growing awareness regarding aptamer applications.

Key players

Key players operating in the aptamers market include Ophthotech Corporation, Aptamer Sciences, Inc., Novartis AG, NeoNeuro SAS, Aptagen LLC, Aptus Biotech S.L., AM Biotechnologies, LLC, Base Pair Biotechnologies, Vivonics Inc., CAGE Bio Inc., TAGCyx Biotechnologies Inc., AstraZeneca, GlyTech, Inc., GC Biopharma Corp., Achiko AG, Agilent Technologies, Inc., SomaLogic Operating Co., Inc., Amsbio, and IVERIC bio, Inc. Ophthotech Corporation dominates the global aptamers market.